STAA Stock On Track For Its Fourth Straight Session Of Gains – This Analyst Would Rather Be Early Than Late On Staar’s Growth Story

• Wedbush said the recovery in China may prompt a valuation re-rating of the stock and multiple expansion to historical levels.
• Canaccord stated that even though it updated its model for Staar Surgical, the company provided very little information compared to its April preannouncement.
• The company reported first-quarter net sales of $93.5 million, beating Wall Street expectations of $78.72 million

Shares of Staar Surgical (STAA) shot up more than 10% on Thursday after multiple analysts turned bullish on the stock following strong quarterly results.

Wedbush updated Staar Surgical to ‘Outperform’ from a ‘Neutral’ rating and hiked its price target to $40 from $26, representing a 53% hike from the firm's previous estimate.

Wedbush Says STAA Has Potential To Exceed Its Bull Case Scenario

Wedbush stated that Staar Surgical’s first-quarter earnings report indicates the company is either at or nearing the inflection point for a full recovery in China, according to TheFly.

The firm also stated that it has taken a long-term bet on the company, as Staar Surgical has the potential to exceed its bull-case scenario in the upcoming quarters, and it would prefer to be early rather than late on Staar Surgical’s growth story.  

It added that the recovery in China may prompt a valuation re-rating of the stock and multiple expansion to historical levels.

Meanwhile, Canaccord increased Staar Surgical’s price target to $32 from $27 and kept a ‘Buy’ rating. The firm noted that the quarterly report provides a strong foundation for the remainder of 2026. However, Canaccord stated that even though it updated its model for the stock, the company provided very little information compared to its April preannouncement. 

Adam Maeder, analyst at Pipe Sandler, raised the company stock price target to $33 from $16. Maeder noted that Staar Surgical’s Chinese business was impressive. He added that the company’s first-quarter results were in line with its preannouncement in April; however, despite a good start to the year, the company did not provide full-year guidance or add more information on the second-quarter outlook.

Staar Surgical’s Q1 Earnings Report

The company reported first-quarter net sales of $93.5 million, beating Wall Street expectations of $78.72 million, while earnings stood at $0.10 per share compared to a loss of $1.10 per share in the year-ago quarter.

Regarding its China business, the company stated that net sales in China were mainly driven by a recovery in in-market demand, positioning it better for the second quarter and the rest of the year.

What Retail Thinks About STAA Stock

On Stocktwits, retail sentiment surrounding the stock has improved to ‘extremely bullish’ from ‘bullish’, while message volume improved to ‘extremely high’ from ‘normal’ in the past 24 hours.

Shares of Staar Surgical have gained more than 38% so far this year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: AMD's Lisa Su Says AI Agents Are Driving ‘Tremendous Demand’, Touts Chipmaker's Portfolio Amid Blowout Q1